Pubmed Veröffentlichungen

Öffnen Sie PUBMED, um eine aktuelle Liste der wissenschaftlichen Arbeiten zu erhalten.

Reinholz M, Poetschke J, Schwaiger H, Epple A, Ruzicka T, Gauglitz GG. The dermatology life quality index as a means to assess life quality in patients with different scar types. J Eur Acad Dermatol Venereol. 2015 Apr 10. doi: 10.1111/jdv.13135.

Reinholz M, Gauglitz GG, Giehl K, Braun-Falco M, Schwaiger H, Schauber J, Ruzicka T, Berneburg M, von Braunmühl T. Non-invasive diagnosis of sweat gland dysplasia using optical coherence tomography and reflectance confocal microscopy in a family with anhidrotic ectodermal dysplasia (Christ-Siemens-Touraine syndrome). J Eur Acad Dermatol Venereol. 2015 Mar 9. doi: 10.1111/jdv.13085.

Gauglitz GG, Bureik D, Zwicker S, Ruzicka T, Wolf R. The Antimicrobial Peptides Psoriasin (S100A7) and Koebnerisin (S100A15) Suppress Extracellular Matrix Production and Proliferation of Human Fibroblasts. Skin Pharmacol Physiol. 2014 Dec 4;28(3):115-123.

Gold MH, Berman B, Clementoni MT, Gauglitz GG, Nahai F, Murcia C. Updated international clinical recommendations on scar management: part 1-evaluating the evidence. Dermatol Surg. 2014 Aug;40(8):817-24. doi: 10.1111/dsu.0000000000000049.

Palm U, Feichtner KB, Hasan A, Gauglitz G, Langguth B, Nitsche MA, Keeser D, Padberg F.The Role of Contact Media at the Skin-electrode Interface During Transcranial Direct Current Stimulation (tDCS). Brain Stimul. 2014 Jun 20. pii: S1935-861X(14)00186-7. doi: 10.1016/j.brs.2014.06.006.

Nast A, Eming S, Fluhr J, Fritz K, Gauglitz GG, Hohenleutner S, Panizzon RG, Sebastian G, Sporbeck B, Koller J. German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids). J Dtsch Dermatol Ges. 2012 Oct;10:747-62

GauglitzGG, BureikD, DombrowskiY, PavicicT, RuzickaTH, SchauberJ. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol. 2012 Aug 31;25:313-318.

Gauglitz GG, Zedler S, Ninkovic M, Spiegel F, Fuhr J, v. Donnersmarck G, Faist E. Functional characterization of cultured keratinocytes after acute cutaneous burn injury. PLoS One. 2012;7:e29942.

Jeschke MG, Finnerty CC, Herndon DN, Song J, Boehning D, Gauglitz GG. Severe injury is associated with insulin resistance, endoplasmic reticulum stress and unfolded protein response. Ann Surg. 2012 Feb;255:370-8.

Gauglitz G, Farwick M, Pavicic T, Köhler T, Wegmann M, Schwach-Abdellaoui K, Malle B, Tarabin V, Schmitz G, Korting HC. Fifty-kDa Hyaluronic Acid Upregulates Some Epidermal Genes without Changing TNF-α Expression in Reconstituted Epidermis. Skin Pharmacol Physiol. 2011;24:210-7.

Farwick M, Pavicic P, Lersch P, Schwach-Abdellaoui K, Malle B, Korting HC, Gauglitz GG. Efficacy of cream-based novel formulations of hyaluronic acid of different molecular size in anti-wrinkle treatment.  J Drugs Dermatol. 2011 Sep 1;10:990-1000.

Sammet SC, Niedermeier A, Bogner J, Mackert M, Gauglitz GG, Ruzicka T. Unusual faces of Syphilis. Hautarzt. 2012 May;63:415-22.

Gauglitz GG, Jeschke MG, Kulp G, Williams FM, Kraft R, Herndon DN. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One. 2011;6:e21245.

Jeschke MG, Kraft R, Song J, Gauglitz GG, Cox RA, Brooks NC, Finnerty CC, Kulp GA, Herndon DN, Boehning D. Insulin Protects against Hepatic Damage Postburn. Mol Med. 2011 5-6;17:516-522.

Gauglitz GG, Lee JO, Herndon DN, Hawkins HK, Halder SC, Jeschke MG. Association Between Dietary Fat Content and Outcomes in Pediatric Burn Patients. J Surg Res. 2010 Nov 4. J Surg Res. 2011 Mar;166:e83-90.

Pavicic T, Ruzicka T, Korting HC, Gauglitz G. Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients. J Drugs Dermatol. 2010 Jun;9:690-5.

Jeschke MG, Gauglitz GG, Song J, KulpGA, Finnerty CC, Cox RA, Barral JM, Herndon DN, Boehning D. Calcium and ER stress mediate hepatic apoptosis after burn injury. J Cell Mol Med. 2009 Aug;13:1857-65.

Gauglitz GG, Halder S, Boehning DF, Kulp GA, Herndon DN, Barral JM, Jeschke MG. Post-burn hepatic insulin resistance is associated with ER stress. Shock. 2010 Mar;33:299-305.

Kita K, Gauglitz GG, Phan TT, Herndon DN, Jeschke MG. Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane. Stem Cells Dev. 2010 Apr;19:491-502.

Gauglitz GG, Toliver-Kinsky TE, Williams FN, Song J, Cui W, Herndon DN, Jeschke MG. Insulin increases resistance to burn wound infection-associated sepsis. Crit Care Med. 2010 Jan;38:202-8.

Gauglitz GG, Herndon DN, Kulp GA, Meyer WJ 3rd, Jeschke MG. Abnormal insulin sensitivity persists up to three years in pediatric patients post-burn. J Clin Endocrinol Metab. 2009 May;94:1656-64.

Song J, Wolf SE, Wu XW, Finnerty CC, Gauglitz GG, Herndon DN, Jeschke MG. Starvation-induced proximal gut mucosal atrophy diminished with aging. J Parenter Enteral Nutr. 2009 Jul-Aug;33:411-6.

Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, Norbury WB, Branski LK, Gauglitz GG, Mlcak RP, Herndon DN. Pathophysiologic response to severe burn injury. Ann Surg. 2008 Sep;248:387-401.

Jeschke MG, Mlcak RP, Finnerty CC, Norbury WB, Przkora R, KulpGA, Gauglitz GG, Zhang XJ, Herndon DN. Gender differences in pediatric burn patients: does it make a difference? Ann Surg. 2008 Jul;248:126-36.

Gauglitz GG, Finnerty CC, Herndon DN, Mlcak RP, Jeschke MG. Are serum cytokines early predictors for the outcome of burn patients with inhalation injuries who do not survive? Crit Care. 2008;12:R81.

Gauglitz GG, Song J, Herndon DN, Finnerty CC, Boehning D, Barral JM, Jeschke MG. Characterization of the inflammatory response during acute and post-acute phases after severe burn. Shock. 2008 Nov;30:503-7.

Jeschke MG, Norbury WB, Finnerty CC, Mlcak RP, KulpGA, Branski LK, Gauglitz GG, Herndon B, Swick A, Herndon DN. Age differences in inflammatory and hypermetabolic postburn responses. Pediatrics. 2008 Mar;121:497-507.

Jeschke MG, Mlcak RP, Finnerty CC, Norbury WB, Gauglitz GG, Kulp GA, Herndon DN. Burn size determines the inflammatory and hypermetabolic response. Crit Care. 2007;11:R90.



Kulichova D, Borovaya A, Ruzicka T, Thomas P, Gauglitz GG. Understanding the safety and tolerability of facial filling therapeutics.Expert Opin Drug Saf. 2014 Sep;13(9):1215-26.

Arno AI, Gauglitz GG, Barret JP, Jeschke MG. New molecular medicine-based scar management strategies. Burns. 2014 Jan 14.

Gauglitz GG, William FN. Overview of the management of the severely burned patient. In: UpToDate, Jeschke, MG (Ed), UpToDate, Duda RB. (Accessed on March 9th, 2014.)

Gauglitz GG, Shahrokhi S. Clinical manifestations, diagnosis, and treatment of burn wound sepsis. In: UpToDate, Jeschke, MG (Ed), UpToDate, Duda RB. (Accessed on March 9th, 2014.)

Gauglitz GG. Management of keloids and hypertrophic scars: current and emerging options. Clinical, cosmetic and investigational dermatology 2013;6:103-14.

Gauglitz GG, Pavicic T. Emerging strategies for the prevention and therapy of excessive scars. MMW Fortschr Med. 2012 Sep 10;154:55-8.

Pavicic T, Gauglitz GG. Modern soft tissue augmentation – away from treating the single fold to volume replacement in the whole face. MMW Fortschr Med. 2012 Sep 10;154:51-2, 54.

Gauglitz GG, Callenberg H, Weindl G, Korting HC. Host defence against candida albicans and the role of pattern-recognition receptors. Acta Derm Venereol. 2012 May;92:291-8

Gauglitz GG, Williams FN, Herndon DN, Jeschke MG. Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs? Curr Opin Clin Nutr Metab Care. 2011 Mar;14:176-81

Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic Scarring and Keloids: Pathomechanisms, Current and Emerging Treatment Strategies.  Mol Med. 2011 Jan-Feb;17:113-25.

Gauglitz GG, Kunte Ch. Hautarzt. Empfehlungen zur Prävention und Therapie hypertropher Narben und Keloide.  2011 May;62(5):337-346.

Jeschke MG, Gauglitz GG, Phan TT, Herndon DN, Kita K. Umbilical cord lining membrane and Wharton’s jelly-derived mesenchymal stem cells: the similarities and differences. Open Tissue Eng Regen Med J. 2011

Gauglitz GG. Behandlung von Keloiden, hypertrophen und atrophen Narben. J Ästhet Chir2011; 4:12–19..

Gauglitz GG. Behandlung von Keloiden. Akt Dermatol 2011; 37:75-80.

Gauglitz GG; Pavicic T, Ruzicka T. Wie sich überschießende Narben behandeln und vermeiden lassen. Hautnah Dermatologie 2011; 3:2-6

Gauglitz GG, Jeschke MG. Combined gene and stem cell therapy for cutaneous wound healing. Mol Pharm. 2011 Oct 3;8(5):1471-9.

Gauglitz GG. Excessive scar formation – prophylactic measures and current treatment methods. Gynäkol. Prax. 2010 34, 615-625.

MecottGA, Al-Mousawi AM, Gauglitz GG, Herndon DN, Jeschke MG. The role of hyperglycemia in burned patients: evidence-based studies. Shock. 2010 Jan;33:5-13.

Gauglitz GG, Pavicic T, Ruzicka T. Management of hypertrophic scars and keloids. MMW Fortschr Med. 2010 Oct 21;152:40-3.

Branski LK, Gauglitz GG, Herndon DN, Jeschke MG. A review of gene and stem cell therapy in cutaneous wound healing. Burns. 2009 Mar;35:171-80.

Gauglitz GG. Adjunct management for hypermetabolism. Up to date 2009.

Gauglitz GG. Prophylaxe und Therapie von überschießenden Narben. Der Privatarzt 2010; Okt/1, 8-10.

Gauglitz GG. Pathophysiologie und Therapie von hypertrophen Narben, Keloiden und atrophen Narben. Haut 05/2010: 208-211.

Gauglitz GG, Herndon DN, Jeschke MG. Insulin resistance postburn: underlying mechanisms and current therapeutic strategies. J Burn Care Res. 2008 Sep-Oct;29:683-94.

Gauglitz GG, Herndon DN, Jeschke MG. Emergency treatment of severely burned pediatric patients: current therapeutic strategies. Future medicine. 2008; 2:761.


Case Reports

Roider EM, Gauglitz G, Flaig MJ, Ruzicka T, Schauber J. Massive granuloma formation after long-term use of dermal fillers. Hautarzt. 2015 Jan 30.

Dietrich A, Gauglitz GG, Pfluger TT, Herzinger T, Braun-Falco M. Syphilitic Aortitis in Secondary Syphilis. JAMA Dermatol. 2014 Mar 5.

Gauglitz GG, Reinholz M, Kaudewitz P, Schauber J, Ruzicka T. Treatment of striae distensae using an ablative Erbium: YAG fractional laser versus a 585-nm pulsed-dye laser. J Cosmet Laser Ther. 2013 Nov 18.

Gauglitz G, Müller DS, Molin S, Ruzicka T, Herzinger T. Becker nevus of the leg with lipoatrophy. JAMA Dermatol. 2013 Sep;149(9):1115-6.

Gauglitz GG, Ruzicka T, Herzinger T. Erythema a computatro. Case Rep Dermatol. 2013 Mar 29;5(1):111-3



Gauglitz GG, Jeschke MG.  Novel Approaches for Wound Repair Therapies. Skin Care, Sandra M. Hayes (ed.), Nova Science Publishers, Inc 2011.

Gauglitz GG, Jeschke MG.  Advanced wound repair therapies: stem cell therapies. Advanced Wound Repair Therapies, Farrar D, Greener B (ed.), Woodhead Publishing Ltd, 2011.

Gauglitz GG, Fischer T, Dornseifer U, Hegyi J, Karrer S. Probleme mit Narben – aktuelle Therapiemöglichkeiten. Fortschritte der praktischen Dermatologie und Venerologie 2010; Ruzicka Th, Wolff H, Thomas P, Prinz J (ed.), Springer Medizin Verlag Heidelberg 2011, Probleme mit Narben – aktuelle Therapiemöglichkeiten 462-467

Gauglitz GG. Keloide. Spezielle dermatologische Behandlungsoptionen mit Imiquimod, Hengge UR (ed.), Thieme Verlag 2. Auflage, 2011.

Gauglitz GG, Jeschke MG.  A potential role of beta blockers in burn wound healing. Wound Healing Society Yearbook: Advances in Wound Care Volume 2.

Gauglitz GG, Herndon DN, Jeschke MG. How should patients with burns be managed in the ICU. The Evidenced Based Practice of Critical Care, Deutschmann CS (ed.), Elsevier, New York 2009.

Gauglitz GG, Herndon DN, Jeschke MG.  Die Pathophysiologie der Verbrennung. Kompendium Verbrennungen, Kamolz LP, Herndon DN, Jeschke MG (ed.), pp. 5-23, Springer-Verlag Wien New York, 2009.

Gauglitz GG, Herndon DN, Jeschke MG. Therapie von Verbrennungsbedingten Infektionskrankheiten. Kompendium Verbrennungen. Kamolz LP, Herndon DN, Jeschke MG (ed.), pp. 145–58, Springer-Verlag Wien New York, 2009.

Gauglitz GG, Herndon DN, Jeschke MG. Burn causes prolonged insulin resistance and hyperglycemia. Intensive Care Yearbook, pp. 719-27, 2009, Springer-Verlag Wien New York, 2009.
Gauglitz GG, Jeschke MG. Acute treatment of severely burned children. Handbook on Burns, Kamolz L, Jeschke MG, Sjöberg S, Wolf SE, Barret JP (ed.), Springer Verlag Wien New York, 2010.

Gauglitz GG, Jeschke MG. Pathophysiological alterations post-burn. Handbook on Burns, Kamolz L, Jeschke MG, Sjöberg S, Wolf SE, Barret JP (ed.), Springer-Verlag Wien New York, 2010.

Williams FM, Gauglitz GG, Herndon DN, Jeschke MG. Burns. Sabiston, Textbook of Surgery, Townsend CM, Beauchamp DR, Evers MB, Mattox KL, Sabiston DC (ed.), Saunders Elsevier, New York 2010.

Gauglitz GG, Jeschke MG. Nutrition in burns. Encyclopedia of Intensive Care Medicine, Vincent JC, Hall J (ed.), Springer-Verlag 2010.

Gauglitz GG, Herndon DN, Williams FN, Jeschke MG. Modulation of the Hypermetabolic Response after Burn Injury. Total burn care, Herndon DN, (ed.), 4rd ed. 2011.

Gauglitz GG, Anwendung von Botulinum-Toxin A. Narbenbehandlung in der Praxis. Gauglitz GG, Kunte Ch, Schauber J (ed.) Uni-Med Science Verlag 2011.

Gauglitz GG, Rekombinantes TGF-beta 3. Narbenbehandlung in der Praxis. Gauglitz GG, Kunte Ch, Schauber J (ed.) Uni-Med Science Verlag 2011.

Gauglitz GG, Interferon, Bleomycin. Narbenbehandlung in der Praxis. Gauglitz GG, Kunte Ch, Schauber J (ed.) Uni-Med Science Verlag 2011.

Gauglitz GG, Silikongele und –pflaster. Narbenbehandlung in der Praxis. Gauglitz GG, Kunte Ch, Schauber J (ed.) Uni-Med Science Verlag 2011.